Assenagon Asset Management S.A. Grows Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. boosted its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 34.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 192,856 shares of the biotechnology company’s stock after acquiring an additional 49,050 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Enanta Pharmaceuticals were worth $1,109,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in shares of Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 1,548 shares during the period. US Bancorp DE boosted its position in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the period. American Century Companies Inc. boosted its position in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 7,287 shares during the period. Quest Partners LLC grew its stake in Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 7,535 shares in the last quarter. Finally, FMR LLC increased its position in shares of Enanta Pharmaceuticals by 18.9% during the third quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 7,839 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Down 0.2 %

Enanta Pharmaceuticals stock opened at $5.53 on Friday. The firm has a market cap of $117.18 million, a P/E ratio of -1.01 and a beta of 0.56. The business has a fifty day moving average of $6.73 and a two-hundred day moving average of $10.46. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.71 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter last year, the company earned ($1.33) earnings per share. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. Equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.93 earnings per share for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright lowered their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Finally, Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.